Current Research Studies

ACNS1833, A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

ACNS1833

Condition(s): Behavioral, Brain Tumor, Low-Grade Glioma, Newly diagnosed, Other, Pilocytic Astrocytoma
Phase: III
Clinicaltrials.gov ID: NCT03871257

What is the goal of the study?

To demonstrate that the efficacy of treatment with selumetinib as measured by event-free survival (EFS) is non-inferior compared to treatment with carboplatin/vincristine (CV) in previously-untreated low-grade glioma (LGG) not associated with BRAFV600E mutations or systemic neurofibromatosis type 1 (NF1).

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Aimee Sato
Study Team Member: HemOnc CRAs, [email protected]